PHAT vs VTRS · rev $132.6M vs rev $7.27B
Phathom Pharmaceuticals Inc (PHAT) versus Viatris Inc (VTRS) — a side-by-side from cached financials, not a winner call.
Phathom Pharmaceuticals Inc (PHAT) is a biotechnology company listed on US.
Viatris Inc (VTRS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported PHAT revenue for 2026-06-30 was $132.6M. Net income was -$48.0M. PHAT currently screens at market cap $622.7M.
Latest reported VTRS revenue for 2026-06-30 was $7.27B. VTRS currently screens at market cap $10.83B.
PHAT currently screens at market cap $622.7M. VTRS currently screens at market cap $10.83B.
Not investment advice. Open the PHAT and VTRS stock pages for the full models.
Not investment advice.